Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 391,277 shares, an increase of 173.2% from the April 30th total of 143,206 shares. Currently, 16.4% of the shares of the stock are sold short. Based on an average trading volume of 5,873,723 shares, the days-to-cover ratio is currently 0.1 days.
Virax Biolabs Group Price Performance
VRAX stock traded down $0.02 during midday trading on Friday, reaching $0.19. The stock had a trading volume of 2,803,936 shares, compared to its average volume of 53,748,104. The business has a fifty day simple moving average of $0.17 and a two-hundred day simple moving average of $0.28. Virax Biolabs Group has a twelve month low of $0.10 and a twelve month high of $1.14.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Virax Biolabs Group currently has an average rating of “Hold” and a consensus price target of $1.00.
Virax Biolabs Group Company Profile
Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.
At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.
Featured Stories
- Five stocks we like better than Virax Biolabs Group
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.
